database / immune
Daptomycin
also known as Cubicin
Skeletal structure drawn from the computed atomic coordinates in PubChem CID 21585658. Carbons are implicit vertices; hydrogens on carbon are suppressed, as in any structural formula. Nothing here is estimated — every atom sits where PubChem placed it.
Research reference only. The observations below are recorded in the cited literature. Nothing here is advice or a recommendation, and no dosing information is published on this site.
Sequence
Primary structure not characterised in the public records this index draws on. Nothing is shown rather than something invented.
A cyclic lipopeptide made by non-ribosomal synthesis, carrying a decanoyl tail and several non-proteinogenic residues.
Molecular data
| molecular formula | C72H101N17O26 |
|---|---|
| molecular weight | 1620.7 Da (PubChem) |
| computed backbone mass | not characterised |
| length | not characterised |
| net charge (pH 7.4) | not characterised |
| mean hydropathy | not characterised |
| half-life | not characterised |
| delivery route | intravenous |
| PubChem CID | 21585658 |
| PDB | not characterised |
| UniProt parent | not characterised |
Mechanism
Calcium-dependent insertion into Gram-positive membranes, causing depolarisation.
Reported targets: bacterial membrane
Experimental structure
No experimental structure of this peptide is deposited in the PDB. Nothing is rendered here — a predicted fold would not be a structure, and this site does not draw one.
Reported effects
Each row is an outcome described in the literature indexed for this peptide. Reported in the cited work — not a claim, not a recommendation.
| reported outcome | where it appears |
|---|---|
| bactericidal activity against Gram-positive organisms | The double-edged sword of daptomycin: a case of daptomycin-induced eosinophi… Oxford medical case reports 2026 |
Registered trials
| NCT | title | status | phase |
|---|---|---|---|
| NCT00295178 | Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in Cellulitis or Erysipe | COMPLETED | PHASE4 |
| NCT00490737 | Safety Study to Evaluate Daptomycin in Non-infected Adults Who Are Either on Hemodialysis or | COMPLETED | PHASE1 |
| NCT03250104 | Antibiotic Stewardship and Infection Control in Patients at High Risk of Developing Infectio | COMPLETED | — |
| NCT00967941 | Vancomycin and Daptomycin Plus Cefazolin for Preoperative Vascular Surgery Prophylaxis | COMPLETED | — |
| NCT06191601 | Interest in Probabilistic Antibiotic Therapy With Broad-spectrum Beta-lactams in Orthopedic | UNKNOWN | — |
Literature (8)
The double-edged sword of daptomycin: a case of daptomycin-induced eosinophilic pneumonia — Oxford medical case reports 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 42583159 · DOI 10.1093/omcr/omag146
Saturated fatty acids enhance daptomycin activity in a Fak-dependent manner in enterococci — Microbiology (Reading, England) 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 42560741 · DOI 10.1099/mic.0.001751
Effects of Cholesterol and Solution pH on Daptomycin-bilayer Interactions — The Journal of membrane biology 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 42667401 · DOI 10.1007/s00232-026-00400-8
Treatment outcomes of daptomycin- and vancomycin-resistant <i>Enterococcus faecium</i> bloodstream infection — JAC-antimicrobial resistance 2026
ObjectivesAmong patients with daptomycin-resistant and vancomycin-resistant Enterococcus faecium bloodstream infection (BSI), the optimal definitive therapy is uncertain. We estimated the dose effect of daptomycin (≥[dose redacted] versus 8 to MethodsAdults with VRE BSI who received linezolid or daptomycin ≥[dose redacted] were included. Post hoc daptomycin MICs were determined by Sensititre broth microdilution (BMD), and episodes with MIC ≥[dose redacted] were analyzed. The primary outcome was 28-day in-hospital mortality.ResultsAmong 130 patients with daptomycin-resistant VRE BSI, 110 received daptomycin and 20 received linezolid. Within the daptomycin group, 28-day mortality was 55.1% (43/78) with daptomycin 8 to P = 0.03]. Among isolates with daptomycin MIC = [dose redacted], 28-day mortality was 54.9% in patients treated with daptomycin 8 to P = 0.04); no benefit was seen for MIC ≥[dose redacted] (P > 0.99). 28-day mortali…
open access ↗ · PMID 42290912 · DOI 10.1093/jacamr/dlag108
Daptomycin Overcomes <i>Listeria monocytogenes</i> Persister Cells Through Strain-Dependent Efficacy and clpP-Mediated Stress Response — Infection and drug resistance 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 42609602 · DOI 10.2147/idr.s569234
Development of Linezolid and Daptomycin resistance in Vancomycin Resistant Enterococcus Faecium During Antibiotic Treatment — FEMS microbiology letters 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 42644769 · DOI 10.1093/femsle/fnag097
Daptomycin-Induced Eosinophilic Pneumonia in a Patient Treated for MRSA Foot Infection: A Case Report — Journal of the American Podiatric Medical Association 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 42496338 · DOI 10.3390/japma116040049
Population pharmacokinetics of daptomycin in patients with haematological malignancies and vancomycin-resistant Enterococcus bloodstream infections — International journal of antimicrobial agents 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 42637177 · DOI 10.1016/j.ijantimicag.2026.107974
Related
KPV
immune · 8 citations
Tuftsin
immune · 8 citations
Thymosin α1
immune · 8 citations
LL-37
immune · 8 citations
Human β-defensin 2
immune · 8 citations
Thymulin
immune · 8 citations